Kyverna Therapeutics Inc (KYTX) ニュース

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors

Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors PR Newswire EMERYVILLE, Calif., Oct. 21...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Kyverna Therapeutics Presents Patient Data Reinforcing Potential of KYV-101 for Treatment of Neuroinflammatory Diseases in Symposium at ECTRIMS 2024

Kyverna Therapeutics Presents Patient Data Reinforcing Potential of KYV-101 for Treatment of Neuroinflammatory...

Form 8-K - Current report

Kyverna Therapeutics Announces Leadership Update

Kyverna Therapeutics Announces Leadership Update PR Newswire EMERYVILLE, Calif., Sept. 16, 2024 – Warner...

Kyverna Therapeutics to Participate in Upcoming September Investor Conferences

Kyverna Therapeutics to Participate in Upcoming September Investor Conferences PR Newswire EMERYVILLE, Calif...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results PR...

Kyverna Therapeutics Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Progressive Myasthenia Gravis

Kyverna Therapeutics Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With...

Form 8-K - Current report